CVRdatabase
Menu

Chr. Olesen Synthesis A/S

Public limited companyCVR 33964870HvidovreActive

Chr. Olesen Synthesis A/S is a public limited company, based in Hvidovre, active in manufacture of basic pharmaceutical products, founded in 2011. Equity was negative at the end of 2025 (−DKK 9.5m). The company went from a profit in 2024 to a loss of DKK 2.3m in 2025. Measured by gross profit, it ranks no. 8 of 14 companies in the industry in the database.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 7m−34.2% vs. 2024
Net profit−DKK 2.3m−131.1% vs. 2024
Equity−DKK 9.5m−32% vs. 2024
Employees97latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • Gross profit fell 34% (2024 → 2025), to DKK 7m.
  • Net profit went from a profit of DKK 7.4m to a loss of DKK 2.3m (2024 → 2025).

Employees

  • 12 more employees than a year earlier: 97 (08/2026) against 85 (08/2025).

Management and owners, last 24 months

  • New in management: Thomas Michael Moestrup (board member, 30/09/2026), Joseph Nivaro (board member, 30/09/2026) and Jean-Francois Hilaire (chair of the board, 30/09/2026).
  • Stepped down: Mads Christian Olesen (chair of the board, 30/09/2026), James Charles Gale (board member, 30/09/2026) and Tibor Simon (board member, 30/09/2026).
  • New owners registered: Samfara/Bidco Limited (30/09/2026).
  • No longer registered as owner: Chr. Olesen A/S (30/09/2026), Signet Healthcare Partners Accredited Partnership III,LP (30/09/2026) and Signet Healthcare Partners QP Partnership III, LP (30/09/2026).

Registrations, last 24 months

  • 15/09/2026: Share capital changed from 538,358 DKK to 567,958 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 15m−DKK 10m−DKK 5mDKK 0DKK 5m202020212022202320242025
EquityNet profit
Financial figures for Chr. Olesen Synthesis A/S
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit1,381−473,6445,42310,5686,959−34.2%
Operating profit (EBIT)−3,052−4,494−1,623−6753,357−1,800−153.6%
Profit before tax−3,273−4,556−2,189−1,5222,380−2,779−216.8%
Net profit−3,273−4,556−2,189−1,5227,392−2,299−131.1%
Total assets12,31310,49612,50714,92322,00624,386+10.8%
Equity−6,316−10,872−13,060−14,583−7,191−9,490−32%
Liabilities18,62921,36825,56729,50529,19733,876+16%
Cash and cash equivalents0––––––
Average number of employees495055616879+16.2%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 5mDKK 0DKK 5mDKK 10mDKK 15mDKK 20mDKK 25m202020212022202320242025
Gross profitMedian, the industry (14 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 9.5m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Chr. Olesen Synthesis A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202513/04/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202428/04/2025The companyPDFXBRL
202301/01/2023 – 31/12/202317/04/2024The companyPDFXBRL
202201/01/2022 – 31/12/202230/03/2023The companyPDFXBRL
202101/01/2021 – 31/12/202125/05/2022The companyPDFXBRL
202001/01/2020 – 31/12/202028/04/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
02040608010009/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/2608/26
Employees

Position in the industry

14 companies in the database

Comparison with the other companies in manufacture of basic pharmaceutical products based on the latest financial year.

Gross profitDKK 7mNo. 8 of 14
Better than 46% of the companies in the industry
Equity−DKK 9.5mNo. 13 of 14
Better than 8% of the companies in the industry
Number of employees97No. 3 of 14
Better than 85% of the companies in the industry

Industry median: gross profit DKK 13.9m, net profit DKK 80,789, equity DKK 10.1m, 19 employees.

DKK 100kDKK 749kDKK 5.6mDKK 42mDKK 161mHere
Distribution of gross profit for 14 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 50–199 employees4,467 companies in the comparison
No. 4,015of 4,412
Better than 9%
No. 4,383of 4,466
Better than 2%
Companies that are between 15 and 29 years old24,910 companies in the comparison
No. 7,795of 24,791
Better than 69%
No. 24,749of 24,909
Better than 1%
All companies of type A/S18,025 companies in the comparison
No. 10,584of 17,786
Better than 40%
No. 17,793of 18,024
Better than 1%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of basic pharmaceutical products
Gross profit
  1. Chr. Olesen Synthesis A/SDKK 7m
  2. Xellia Pharmaceuticals ApSDKK 314.9m
  3. Glycom Manufacturing A/SDKK 226.3m
Net profit
  1. Chr. Olesen Synthesis A/S−DKK 2.3m
  2. Xellia Pharmaceuticals ApSDKK 213.7m
  3. Glycom Manufacturing A/SDKK 69.2m
Equity
  1. Chr. Olesen Synthesis A/S−DKK 9.5m
  2. Xellia Pharmaceuticals ApSDKK 404.6m
  3. Glycom Manufacturing A/SDKK 577.7m
Employees
  1. Chr. Olesen Synthesis A/S97
  2. Xellia Pharmaceuticals ApS458
  3. Glycom Manufacturing A/S116

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Samfara/Bidco Limited100%
Chr. Olesen Synthesis A/S

Management

4 active registrations

Executive management

Executive management at Chr. Olesen Synthesis A/S
NameRoleAppointed
Thomas Michael MoestrupCEO01/07/2018

Board of directors

Board of directors at Chr. Olesen Synthesis A/S
NameRoleAppointed
Thomas Michael MoestrupBoard member30/09/2026
Joseph NivaroBoard member30/09/2026
Jean-Francois HilaireChair of the board30/09/2026
Founders
Chr. Olesen Pharmaceuticals A/S
Former management (9)
Former management at Chr. Olesen Synthesis A/S
NameRoleAppointedResigned
Svend Aage JohansenBoard member17/10/201130/09/2015
Allan ArdensøBoard member17/10/201101/05/2012
Mads Christian OlesenChair of the board17/10/201130/09/2026
Svend Aage JohansenDirector18/10/201101/01/2012
Terje AarboghDirector01/01/201230/06/2018
Terje AarboghBoard member01/05/201230/06/2018
James Charles GaleBoard member30/09/201530/09/2026
Tibor SimonBoard member01/10/201530/09/2026
Jørgen Damsbo AndersenBoard member15/06/201631/05/2018

Signing rule: Selskabet tegnes af den samlede bestyrelse, ét bestyrelsesmedlem i forening med en direktør eller én direktør.

Address and production units

1 active production units

Kanalholmen 8
2650 Hvidovre

Hvidovre Municipality · Postcode 2650

Production units
Production unitAddressEmployeesP number
CHR. OLESEN SYNTHESIS A/SKanalholmen 8-12, 2650 Hvidovre971017196959

Purpose

Selskabets formål er produktion af aktive pharmaceutiske ingredienser samt hermed beslægtet virksomhed.

The purpose is quoted from the register in Danish.

Changes year by year

50 registered events
202612 changesmanagement 6 · ownership 4 · capital 1 · accounts 1
  • Jean-Francois Hilaire appointed chair of the board
  • Joseph Nivaro appointed board member
  • Thomas Michael Moestrup appointed board member
  • Tibor Simon stepped down as board member
  • James Charles Gale stepped down as board member
  • Mads Christian Olesen stepped down as chair of the board
  • Samfara/Bidco Limited registered as owner (100%)
  • CHR. OLESEN A/S is no longer registered as owner
  • Signet Healthcare Partners Accredited Partnership III,LP is no longer registered as owner
  • Signet Healthcare Partners QP Partnership III, LP is no longer registered as owner
  • Share capital changed from 538,358 DKK to 567,958 DKK
  • Annual report for 2025 published
20251 changeaccounts 1
  • Annual report for 2024 published
20241 changeaccounts 1
  • Annual report for 2023 published
20231 changeaccounts 1
  • Annual report for 2022 published
20221 changeaccounts 1
  • Annual report for 2021 published
20211 changeaccounts 1
  • Annual report for 2020 published
20185 changesaddress 1 · management 4
  • Moved to Kanalholmen 8-12, 2650 Hvidovre
  • Thomas Michael Moestrup appointed ceo
  • Terje Aarbogh stepped down as board member
  • Terje Aarbogh stepped down as director
  • Jørgen Damsbo Andersen stepped down as board member
20161 changemanagement 1
  • Jørgen Damsbo Andersen appointed board member
201510 changesmanagement 3 · capital 1 · ownership 6
  • Tibor Simon appointed board member
  • Share capital changed from 269,179 EUR to 538,358 DKK
  • James Charles Gale appointed board member
  • Svend Aage Johansen stepped down as board member
  • CHR. OLESEN A/S registered as owner (50%)
  • Signet Healthcare Partners Accredited Partnership III,LP registered as owner (5%)
  • Signet Healthcare Partners QP Partnership III, LP registered as owner (33.33%)
  • CHR. OLESEN A/S is no longer registered as owner
  • AARBOGH BUSINESS PARTNER HOLDING ApS is no longer registered as owner
  • CHRISJOPALI ApS is no longer registered as owner
20141 changecapital 1
  • Share capital changed from 2,000,000 DKK to 269,179 EUR
20133 changesownership 3
  • CHR. OLESEN A/S registered as owner (50%)
  • AARBOGH BUSINESS PARTNER HOLDING ApS registered as owner (15%)
  • CHRISJOPALI ApS registered as owner (25%)
20124 changesmanagement 4
  • Terje Aarbogh appointed board member
  • Allan Ardensø stepped down as board member
  • Terje Aarbogh appointed director
  • Svend Aage Johansen stepped down as director
20119 changescapital 1 · address 3 · management 4 · founded 1
  • Share capital changed from 500,000 DKK to 2,000,000 DKK
  • Moved to Kanalholmen 8-12, 2650 Hvidovre
  • Moved to Jægersborg Alle 164, 2820 Gentofte
  • Moved to Kanalholmen 8-12, 2650 Hvidovre
  • Svend Aage Johansen appointed director
  • Registered as CHR. OLESEN SYNTHESIS A/S
  • Svend Aage Johansen appointed board member
  • Mads Christian Olesen appointed chair of the board
  • Allan Ardensø appointed board member

Related companies

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction